Hans-Jürgen Federsel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/373725/publications.pdf

Version: 2024-02-01

40 papers

1,108 citations

430874 18 h-index 395702 33 g-index

43 all docs 43 docs citations

43 times ranked

1278 citing authors

#	Article	IF	CITATIONS
1	Crystal structures of the <i>Chromobacteriumâ$\in f$violaceum</i> i\"i\"\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	4.7	108
2	Route Design in the 21st Century: The IC $\langle i \rangle$ SYNTH $\langle i \rangle$ Software Tool as an Idea Generator for Synthesis Prediction. Organic Process Research and Development, 2015, 19, 357-368.	2.7	106
3	Chlorodifluoromethyl phenyl sulfone: a novel non-ozone-depleting substance-based difluorocarbene reagent for O- and N-difluoromethylations. Chemical Communications, 2007, , 5149.	4.1	89
4	Asymmetry on large scale: the roadmap to stereoselective processes. Nature Reviews Drug Discovery, 2005, 4, 685-697.	46.4	85
5	Recent Trends in Enzyme Immobilizationâ€"Concepts for Expanding the Biocatalysis Toolbox. Molecules, 2021, 26, 2822.	3.8	71
6	Facing chirality in the 21st century: Approaching the challenges in the pharmaceutical industry. Chirality, 2003, 15, S128-S142.	2.6	69
7	Chemical Process Research and Development in the 21st Century: Challenges, Strategies, and Solutions from a Pharmaceutical Industry Perspective. Accounts of Chemical Research, 2009, 42, 671-680.	15.6	65
8	Mechanism of the Asymmetric Sulfoxidation in the Esomeprazole Process: Effects of the Imidazole Backbone for the Enantioselection. Advanced Synthesis and Catalysis, 2009, 351, 903-919.	4.3	46
9	Key Amino Acid Residues for Reversed or Improved Enantiospecificity of an ï‰â€ ransaminase. ChemCatChem, 2012, 4, 1167-1172.	3.7	45
10	In search of sustainability: process R&D in light of current pharmaceutical industry challenges. Drug Discovery Today, 2006, 11, 966-974.	6.4	42
11	Dichloromethane as reactant in synthesis: an expedient transformation of prolinamide to a novel pyrrolo[1,2-c]imidazolone. Journal of Organic Chemistry, 1990, 55, 2254-2256.	3.2	37
12	Logistics of process R&D: transforming laboratory methods to manufacturing scale. Nature Reviews Drug Discovery, 2003, 2, 654-664.	46.4	37
13	Construction of a Chiral Central Nervous System (CNS)-Active Aminotetralin Drug Compound Based on a Synthesis Strategy Using Multitasking Properties of (<i>S</i>)-1-Phenylethylamine. Accounts of Chemical Research, 2007, 40, 1377-1384.	15.6	36
14	Optimization and Scale-up of a Pd-Catalyzed Aromatic Câ^'N Bond Formation: A Key Step in the Synthesis of a Novel 5-HT _{1B} Receptor Antagonist. Organic Process Research and Development, 2008, 12, 512-521.	2.7	36
15	En route to full implementation: driving the green chemistry agenda in the pharmaceutical industry. Green Chemistry, 2013, 15, 3105.	9.0	32
16	Process R&D under the magnifying glass: Organization, business model, challenges, and scientific context. Bioorganic and Medicinal Chemistry, 2010, 18, 5775-5794.	3.0	25
17	A novel base-induced ring expansion of quaternized heterocycles. Tetrahedron Letters, 1980, 21, 2429-2432.	1.4	23
18	An Efficient Synthesis of a New, Chiral 2',6'-Pipecoloxylidide Local Anaesthetic Agent Acta Chemica Scandinavica, 1987, 41b, 757-761.	0.7	21

#	Article	IF	Citations
19	Factors influencing the selectivity in asymmetric oxidation of sulfides attached to nitrogen containing heterocycles. Chemical Communications, 2007, , 2187.	4.1	19
20	Development of a Process for a Chiral Aminochroman Antidepressant:  A Case Story. Organic Process Research and Development, 2000, 4, 362-369.	2.7	16
21	Handing Over the Baton: Connecting Medicinal Chemistry with Process R& D. Drug News and Perspectives, 2008, 21, 193.	1.5	16
22	Building bridges from process R&D: from a customer–supplier relationship to full partnership. Pharmaceutical Science & Technology Today, 2000, 3, 265-272.	0.7	10
23	Start small, think big â€" the art of process R&D. Nature Reviews Drug Discovery, 2002, 1, 1013-1013.	46.4	10
24	Recent Advances in Asymmetric Hydrogenation Catalysis Utilizing Spiro and Other Rigid C-Stereogenic Phosphine Ligands. Journal of Organic Chemistry, 2022, 87, 1898-1924.	3.2	10
25	Drug discoverers –you need us!. Drug Discovery Today, 2001, 6, 397-398.	6.4	8
26	Rapid Rearrangement of Quaternized Oxazoles and Thiazoles through Base Treatment. Heterocycles, 1980, 14, 33.	0.7	6
27	The Integration of Process R&D in Drug Discovery - Challenges and Opportunities. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 79-86.	1.1	6
28	In Praise of Collaboration: The INTENANT Success Story. Organic Process Research and Development, 2012, 16, 260-261.	2.7	5
29	Regioisomerism in the Synthesis of a Chiral Aminotetralin Drug Compound: Unraveling Mechanistic Details and Diastereomer-Specific In-Depth NMR Investigations. Journal of Organic Chemistry, 2012, 77, 5503-5514.	3.2	4
30	How to conduct research in the pharmaceutical industry? Facing the dilemma: small, autonomous teams versus large, integrated centers. Expert Opinion on Drug Discovery, 2010, 5, 813-818.	5.0	3
31	Taking the Green Road Towards Pharmaceutical Manufacturing. Synthesis, 2022, 54, 4257-4271.	2.3	3
32	Drug discoverers – you need us! – Reply. Drug Discovery Today, 2001, 6, 1046-1047.	6.4	2
33	In the Limelight: Carbon–Heteroatom Coupling Chemistry. Organic Process Research and Development, 2014, 18, 179-179.	2.7	2
34	Catalytic Câ€"H Arylations as a Tool for Making Pharmaceuticals. Organic Process Research and Development, 2015, 19, 259-259.	2.7	2
35	SPECIAL FEATURE SECTION:ÂASYMMETRIC SYNTHESIS ON LARGE SCALE. Organic Process Research and Development, 2007, 11, 494-494.	2.7	1
36	Invited Academic Review Focused on Catalytic Reductions. Organic Process Research and Development, 2014, 18, 288-288.	2.7	1

#	Article	IF	CITATIONS
37	To Overcome the Hurdles., 2007,, 111-135.		1
38	Invited Academic Review. Organic Process Research and Development, 2013, 17, 750-750.	2.7	0
39	Invited Academic Review on Late-Stage Fluorination. Organic Process Research and Development, 2014, 18, 473-473.	2.7	O
40	An unbalanced portfolio. Drug News and Perspectives, 2009, 22, 287.	1.5	0